533 Bryant Street
44 articles with Horizon Therapeutics
AGC Biologics, a leading global biopharmaceutical Contract Development and Manufacturing Organization, announced that its partnership with Horizon Therapeutics plc is expanding to produce Horizon's Thyroid Eye Disease treatment, TEPEZZA, at AGC's new facility in Boulder, CO.
Horizon Therapeutics plc (NASDAQ: HZNP) today announced that it has been named to the Crain’s Chicago Business 2020 Best Places to Work in Chicago list. “It’s a tremendous honor that Crain’s Chicago Business ranked us among the Best Places to Work in Chicago where many Horizon employees live and work,” said Tim Walbert, chairman, president and chief executive officer, Horizon. “Despite these challenging times, working at
Horizon Therapeutics plc announced the pricing of its underwritten public offering of 11,800,000 of its ordinary shares at a price to the public of $71.00 per share.
New Topline TEPEZZA® (teprotumumab-trbw) Data Underscore its Efficacy in Longer Disease Duration, Long-Term Durability and Potential for Retreatment in People Living with Thyroid Eye Disease (TED)
89 percent of patients who received placebo during the OPTIC Phase 3 clinical trial and then received TEPEZZA in the OPTIC-X extension trial achieved clinically significant proptosis reduction with an average of 12 months of disease, compared with six months in OPTIC
U.S. Physician Survey Illustrates the Devastating Impact of Thyroid Eye Disease on Patient Quality of Life
In an analysis accepted for presentation at the American Association of Clinical Endocrinologists (AACE) Annual Scientific & Clinical Congress, physicians cite psychological well-being and ability to function in social situations as most impacted by the disease
Horizon Therapeutics plc Reports Strong First-Quarter 2020 Financial Results; Increasing TEPEZZA™ Full-Year 2020 Net Sales Guidance to Greater Than $200 Million Due to Rapid Uptake; Increasing Full-Year 2020 Net Sales Guidance
First-Quarter 2020 Net Sales of $355.9 Million Increased 27 Percent; First-Quarter 2020 GAAP Net Loss of $13.6 Million; Adjusted EBITDA of $107.2 Million
Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product Candidate to Expand Development-Stage Pipeline
Gained Rights to Product Candidate, CZN001 (renamed HZN-825), a Potential Treatment for Diffuse Cutaneous Systemic Sclerosis; a Rare Rheumatic Disease with No FDA-Approved Treatment
4/2/2020Biopharma companies from across the globe provide updates on their pipelines and business practices.
TEPEZZA™ (teprotumumab-trbw) Significantly Reduces Proptosis (Eye Bulging), a Key Marker of Thyroid Eye Disease, Across Patient Subtypes
Data presented as part of ENDO 2020 demonstrates proptosis response regardless of age, gender and smoking status
3/9/2020Although March looks to be a busy month for the U.S. Food and Drug Administration, several of the PDUFA dates for this week were for drugs under Priority Review.
Horizon Therapeutics plc Launches the Down and Out Kidney Campaign to Call Attention to the Prevalence and Impact of Gout in Chronic Kidney Disease
Recent Data Supports Urgent Need to Address Uric Acid Accumulation and Protect the Kidney
These prices refer to the company’s list price. Most patients will not pay that price because of various forms of health insurance or patient assistance programs.
Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2019 Financial Results and Host Webcast on Feb. 26, 2020
Horizon Therapeutics plc announced that its fourth-quarter and full-year 2019 financial results will be released on Wednesday, Feb. 26, 2020.
Horizon Therapeutics plc announced changes to its research and development organization structure.
The New England Journal of Medicine Publishes Comprehensive Data from Phase 3 Clinical Trial (OPTIC) of TEPEZZA™ (teprotumumab-trbw) for Thyroid Eye Disease
Phase 3 trial achieved its primary endpoint and all secondary endpoints with marked improvement in key indicators of disease
1/20/2020There were plenty of clinical trial announcements this week. Here's a look.
1/16/2020Companies from across the globe provide updates to their business and pipeline.
Rosalind Franklin University of Medicine and Science announced that its new Helix 51 incubator has garnered corporate support from Horizon Therapeutics.
MIRROR Open-Label Study Topline Data of Methotrexate with KRYSTEXXA (pegloticase injection) Indicates Significant Improvement in Response Rate
Horizon Therapeutics plc announced topline results from its MIRROR open-label study in which methotrexate with KRYSTEXXA® provided an increased durability of response for people living with chronic gout refractory to conventional therapies – also known as uncontrolled gout.
Horizon Therapeutics plc Increases Peak U.S. Annual Net Sales Expectations for Key Growth Drivers; Provides Update on Several Pipeline Programs
Horizon Therapeutics plc announced that it is increasing the peak U.S. annual net sales expectations for its key growth drivers KRYSTEXXA and teprotumumab, as well as providing several pipeline updates..